-$0.36 EPS Expected for Chimerix Inc (CMRX) This Quarter

Wall Street brokerages forecast that Chimerix Inc (NASDAQ:CMRX) will post earnings per share (EPS) of ($0.36) for the current quarter, according to Zacks. Four analysts have provided estimates for Chimerix’s earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.31). Chimerix posted earnings of ($0.41) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 12.2%. The firm is expected to issue its next quarterly earnings results on Thursday, March 7th.

On average, analysts expect that Chimerix will report full-year earnings of ($1.50) per share for the current year, with EPS estimates ranging from ($1.57) to ($1.45). For the next financial year, analysts expect that the business will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.85) to ($1.22). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Chimerix.

Several analysts recently commented on CMRX shares. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Wednesday, November 14th. HC Wainwright reaffirmed a “buy” rating on shares of Chimerix in a report on Wednesday, February 6th. ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Cowen reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Chimerix in a report on Thursday, October 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $6.17.

Several institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in shares of Chimerix in the fourth quarter worth $26,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Chimerix by 5.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 292,345 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 15,453 shares during the period. Acadian Asset Management LLC grew its holdings in Chimerix by 8.3% during the fourth quarter. Acadian Asset Management LLC now owns 234,156 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 17,868 shares during the period. Rhumbline Advisers grew its holdings in Chimerix by 45.7% during the fourth quarter. Rhumbline Advisers now owns 65,845 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 20,654 shares during the period. Finally, Leisure Capital Management bought a new stake in Chimerix during the third quarter valued at about $108,000. 73.10% of the stock is owned by institutional investors.

Shares of Chimerix stock traded up $0.01 on Tuesday, reaching $2.26. The company’s stock had a trading volume of 402 shares, compared to its average volume of 242,325. The firm has a market cap of $111.59 million, a price-to-earnings ratio of -1.50 and a beta of 1.39. Chimerix has a 52 week low of $2.08 and a 52 week high of $5.94.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply